WHO WE ARE
We are ViiV Healthcare: a specialist pharmaceutical company 100% dedicated to HIV medicines and research and focused on people living with HIV and AIDS.
At ViiV Healthcare we do things differently. From our unique origins to our innovative medicines, we push the boundaries of what people think is possible in HIV treatment and care.
If you should know one thing about us, know this: we will not rest until we leave no person living with HIV behind. Until the 39 million people living with HIV is down to zero, we will continue searching for new ways to limit the impact of HIV.[1]
Born out of a partnership between GSK and Pfizer in 2009, with Shionogi joining in 2012, at ViiV Healthcare we are determined to help end the HIV epidemic. Our one focused goal unites our employees located across the globe, with their expertise in research, manufacturing, policy and more, all guided by our mission to be here until HIV isn’t.
Our product portfolio consists of 17 prescription medicines, in the HIV space. This is only the beginning as our research centre in Branford, Connecticut, USA, the world’s only HIV-dedicated facility, which is utterly focused on finding new innovative medicines to help improve the lives of people living with HIV.
Alongside our novel approach to R&D, improving access to medicines is just as important in delivering results for our patients. At ViiV Healthcare we are dedicated to widening access to ensure those who need our medicines can receive them. Collaborations with organisations such as IAS, CHAI and MPP enable our medicines to make the greatest possible impact in countries around the world. As an example, our voluntary licence agreements allow generic manufacturers to develop paediatric formulations of our medicines where 99% of children living with HIV live. We are committed to working ever closer with our partners through continued access initiatives.
To accelerate the HIV response, we put significant focus on community initiatives to strengthen local healthcare services for people living with HIV. Through our Positive Action programmes, which back over 300 projects worldwide, our work with local communities aim to deliver long-lasting impacts on groups such as women and children. We seek to enhance local expertise and resources that build towards global goals, as well as our own dedicated mission of leaving no person living with HIV behind.
References:
- UNAIDS Global HIV & AIDS Statistics – 2020 Fact Sheet. Available from: https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf. Last accessed: February 2021
YOU MAY ALSO BE INTERESTED IN
Our leadership, which includes our Executive Team and our Board, is responsible for the management of the business and is committed to advancing the HIV response to ensure we leave no person living with HIV behind.
Together we are engaged in the HIV response throughout the world, supported by a team of over 1,100 dedicated ViiV Healthcare staff working across the globe.
For Investors and Media
Find out more about our recent press releases, news updates and conference information here.
NP-GBL-HVX-COCO-220013 February 2025.
If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the GSK Reporting Tool link https://gsk.public.reportum.com/. By reporting side effects, you can help provide more information on the safety of this medicine.
If you are from outside the UK, you can report adverse events to GSK/ ViiV by selecting your region and market, here.
